First Read: Cury "A top line beat to UBSe; record ROE ~80%; REF..."

研报英文原文证据摘录

First Read: Cury "A top line beat to UBSe; record ROE ~80%; REF..."

UBS.com and any other system or distribution method

specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing

UBS Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative

electronic means.

All UBS Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo. Where UBS

Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab and you would like to access that data please

contact your UBS sales representative. UBS Evidence Lab data is available on UBS Neo. The level and types of services provided by UBS Global Research

and UBS Evidence Lab to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of

receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.),

the size and scope of the overall client relationship with UBS Global Research and UBS Evidence Lab and legal and regulatory constraints. UBS HOLT and

UBS Pharma Values are offerings of UBS Global Research. HOLT Lens is a corporate performance platform offering that provides an objective accounting-

led framework for comparing and valuing companies and is available to clients of UBS Global Research; for further details and pricing please contact your

UBS Sales representative. In particular, HOLT has a variety of warranted prices based on the scenario chosen; please mail UBS Securities LLC, 11 Madison